COPENHAGEN (Reuters) -Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S.

Novo Nordisk's U.S.-listed shares fell more than 5% Monday after the drugmaker revealed the latest results for a new ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

Hims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. The breakup came after Novo raised concerns about Hims selling ...

Hims & Hers Health (NYSE:HIMS) stock plunged 20% after pharmaceutical giant Novo Nordisk (NYSE:NVO) announced it would terminate its collaboration with the telehealth company over the sale of weight ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health ...

Novo Nordisk ended its agreement with Hims & Hers for the sale of Wegovy after disagreements over marketing tactics and ...

Novo Nordisk has ended its collaboration with Hims & Hers Health for its Wegovy weight-loss blockbuster treatment roughly a month after it began over concerns about what it said was illegal mass ...

June 22 (Reuters) - Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other ...